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Abstract
Homologous to the E6-associated protein carboxyl terminus domain containing 3 (HECTD3) is an E3 ubiquitin
ligase with unknown functions. Here, we show that HECTD3 confers cancer cell resistance to cisplatin. To under-
stand the molecular mechanisms, we performed a yeast two-hybrid analysis and identified mucosa-associated
lymphoid tissue 1 (MALT1) as an HECTD3-interacting protein. HECTD3 promotes MALT1 ubiquitination with non-
degradative polyubiquitin chains by direct interacting with the MALT1 through its N-terminal destruction of cyclin
domain. HECTD3 does not target MALT1 for degradation but stabilize it. HECTD3 depletion dramatically decreases
the levels of MALT1 in MCF7 and HeLa cells treated with cisplatin, which is correlated to an increase in apoptosis.
Knockdown of MALT1 likewise increases cisplatin-induced apoptosis in these cancer cells. However, HECTD3 over-
expression leads to a decreased cisplatin-induced apoptosis, whereas overexpression of MALT1 partially rescues
HECTD3 depletion–induced apoptosis. These findings suggest that HECTD3 promotes cell survival through stabi-
lizing MALT1. Our data have important implications in cancer therapy by providing novel molecular targets.
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Introduction
Ubiquitination is a posttranslational protein modification involved
in regulating a variety of cellular processes, including cell cycle and ap-
optosis that play key roles in cancer development. Ubiquitin (Ub)
chains are assembled in a three-step enzymatic reaction carried out
by Ub-activating enzymes (E1), Ub-conjugating enzymes (E2), and
Ub-protein ligases (E3). E3 ligases play important roles in cancer develop-
ment because they control substrate specificity and many have been
shown to act as oncoproteins or tumor suppressors because of their
genetic and expression alterations in cancer [1]. Ub is conjugated either
as a single moiety (mono-Ub) or as poly-Ub chains that are generally
linked through K48, K63, or other lysine residues. Different types of
poly-Ub chains have different functions: K48-linked poly-Ub chains
target substrates for proteasomal degradation, whereas K63-linked
poly-Ub chains lead to non-degradative signaling processes [2].
The homologous to the E6-associated protein carboxyl terminus
domain containing 3 (HECTD3) E3 ligase contains an HECT domain
at the C terminus and a destruction of cyclin (DOC) domain at the
N terminus that is responsible for substrate recognition in several
E3 ligases such as the anaphase-promoting complex subunit 10
(APC10/DOC1) [3], PARC, CUL7, and HERC2 [4]. Likewise,
an N-terminal truncated HECTD3 has been shown to target Trio-
associated repeat on actin (Tara) for Ub-mediated degradation [5],
and HECTD3 was reported to interact with and ubiquitinate
Syntaxin 8 [6]. However, to date, the functions of HECTD3 have
not been clearly illustrated.
Mucosa-associated lymphoid tissue 1 (MALT1) is well known to
mediate the T cell antigen receptor– and B cell antigen receptor–induced
signaling to the transcription factor nuclear factor-kappa B (NF-κB).
MALT1 is ubiquitinated by TRAF6 with K63-linked poly-Ub chains,
which activates the NF-κB pathway [7]. Additionally, MALT1 can
function as a paracaspase to cleave multiple NF-κB inhibitors, includ-
ing A20 [8], RelB [9], and CYLD [10] in response to T cell antigen
receptor signaling. Finally, MALT1 interacts with Caspase-8 and pro-
motes Caspase-8–mediated FLIPL cleavage [11]. These studies suggest
that MALT1 may regulate apoptosis.
Here, we demonstrate that HECTD3 promotes cell survival from
cisplatin via a direct interaction with MALT1. HECTD3 modifies
MALT1 with non-degradative poly-Ub chains and increases protein
stability of MALT1. These results suggest that HECTD3 is a pro-




The anti-HECTD3 rabbit polyclonal antibody (Ab) was generated
using a synthesized peptide from the C terminus of HECTD3
(753CRKLTRFEDFEPSDSR768; Invitrogen, Grand Island, NY).
The anti–β-actin mouse monoclonal Ab AC-15 (#A5441), the anti-
Flag rabbit polyclonal Ab (#F7425), the anti-PARP (rabbit, #9915),
anti–cl-Caspase-7 (rabbit, #9491), anti–Caspase-9 (rabbit, #9502),
anti–Caspase-8 (mouse, #9746), and anti–Caspase-3 (rabbit, #9915)
Abs are from Cell Signaling (Danvers, MA). Anti-MALT1 (mouse,
#sc46677), anti-ERα (rabbit, #7207), and anti–human influenza
hemagglutinin (HA) (rabbit, #sc-805) Abs are from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti–glutathione S -transferase
(GST) (rabbit, #G7781) and anti-Flag M2 monoclonal Ab (mouse,
#F3165) were from Sigma (St Louis, MO).
Plasmids
The full-length HECTD3 gene was cloned into the BamHI and
SacII sites of the pLenti6/V5-D vector (Invitrogen). To facilitate pro-
tein immunoprecipitation (IP), a Flag tag was added to the N terminus
of HECTD3 as necessary. The deletion and truncation mutants of
Flag-HECTD3 (Δ512-861 and Δ109-393) were generated by a poly-
merase chain reaction–based approach. The pEBG vector was used to
express GST-fused truncated HECTD3 proteins and DD of MALT1.
Dr Daniel Krappmann generously provided pEF 3×Flag-MALT1 as a
gift (German National Research Center for Environment and Health).
HA-Ub and mutants (K0, K48-only, K63-only, K48R, and K63R)
were gifts from Dr James Zhijian Chen (University of Texas South-
western Medical Center).
Cell Culture and Transfection
MCF7 was cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5%FBS, 0.1 mMNEAA, 1.5 g/l sodium
bicarbonate, and 1 mM sodium pyruvate. MDA-MB-231 was cultured
in DMEM supplemented with 2 mM L-glutamine, 0.1 mM NEAA,
1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate, and 10% FBS.
HeLa and HEK293T cells were cultured in DMEM supplemented
with 5% FBS.
Plasmid and siRNA transfection was performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocols. All chem-
ically synthesized siRNA were purchased from Ambion (Austin, TX)
and transfected at 25 nM final concentration. The siRNA target
sequence for human HECTD3 gene are 5′-GCGGGAACTAGGG-
TTGAAT-3′ (Hsi#1) and 5′-GGTATTTCACCTCTTAAGA-3′
(Hsi#2). The siRNA target sequences for the human MALT1 gene
are 5′-GATCGAGACAGTCAAGATA-3′ (#1) and 5′-GCATTGCC-
TCTATACCAGA-3′ (#2). The siRNA target sequence for human
CASP8 gene is 5′-GATAATCAACGACTATGAA-3′.
Yeast Two-Hybrid Screening
We used the Gal4-based yeast Matchmaker Two-Hybrid Systems
to screen the substrates for HECTD3. The N terminus of HECTD3
without the HECT domain (HΔ512-861) was used as bait. The
DNA fragment encoding HΔ512-861 was cloned into EcoRI and
BamHI sites of pGBK7 vector, and the bait protein was expressed
as a fusion to the Gal4 DNA-binding domain. The library of prey
proteins was expressed as fusions to the Gal4 activation domain.
Screening and validation were performed according to the manufac-
turer’s protocols.
IP and GST Pull-down
Our previous studies described IP using anti-Flag M2-Agarose
(A2220; Sigma) and GST pull-down experiments [12]. The anti-
HECTD3 rabbit polyclonal Ab was used to immunoprecipitate
the endogenous HECTD3 protein from HeLa. Rabbit IgG was used
as the negative control. The beads were washed five times with
500 μl of 1× cell lysis buffer. Proteins were resuspended with 30 μl
of sodium dodecyl sulfate (SDS) sample loading buffer and analyzed
by Western blot.
Purification of the HECTD3 DOC Domain
and the MALT1 DD
DNA fragments representing the DOC domain of HECTD3
(240-378) was polymerase chain reaction–amplified from the full-
length HECTD3 plasmid and inserted into the pGEX-6P-1 between
40 HECTD3 Stabilizes MALT1 Li et al. Neoplasia Vol. 15, No. 1, 2013
the BamHI and EcoRI sites. The construct was verified by DNA
sequencing. For protein expression, Escherichia coli strain Rosetta 2
(DE3) (Novagen, Philadelphia, PA) bearing the expression plasmid
were grown at 37°C to 0.8 absorbance of OD600, then induced with
0.2 mM isopropyl-β-D-thiogalactopyranoside at 15°C for 12 hours,
and harvested by centrifugation. After sonication of the bacteria,
soluble DOC domain was affinity purified through a glutathione
Sepharose 4B column (GE HealthCare, Pittsburgh, PA). The GST-
DOC fusion protein was digested with the PreScission protease (GE
HealthCare) and reloaded to the glutathione Sepharose column to
remove the free GST. The flow-through fractions containing the
DOC domain was concentrated and further purified through a S200
Superdex column (GE HealthCare). The MALT1 DD was expressed
and purified as a His-tag fusion protein as described [13].
BIAcore Analysis
The affinity and kinetic analyses of the interactions between the
HECTD3 DOC domain and the DD of MALT1 were determined
at 25°C using the surface plasmon resonance (SPR) detections with
a BIAcore 3000 System (GE HealthCare). Briefly, MALT1 DD was
immobilized (∼460 RU) onto a CM4 sensor chip (GE HealthCare),
as described for other systems [14]. The HECTD3 DOC domain
(8–0.5 μM) was injected as the analyte sample with two-fold dilu-
tions. Association and dissociation rates (K on/K off), as well as the dis-
sociation constant (K d), were obtained by global fitting of the SPR
data from multiple concentrations to a simple 1:1 Langmuir binding
model, using the BIA evaluation software 4.1 (GE HealthCare).
MALT1 Ubiquitination
HEK293T cells were transiently transfected with HA-Ub and
other plasmids as necessary in six-well plates. Two days after trans-
fection, cells were harvested in 150 μl of SDS lysis buffer (50 mM
Tris-Cl, pH 6.8, 1.5% SDS). The samples were boiled for 15 minutes.
We diluted 100 μl of protein lysate with 1.2 ml of EBC/BSA buffer
(50 mM Tris-Cl, pH 6.8, 180 mM NaCl, 0.5% CA630, 0.5%
BSA) and incubated with anti-Flag M2-Agarose overnight at 4°C with
rotation. The beads were collected by centrifugation at 10,000g for
30 seconds at 4°C and washed three times with 1 ml of ice-cold
EBC/BSA buffer. Proteins were resuspended with 30 μl of SDS sample
loading buffer and analyzed by Western blot using the anti-HA Ab.
Apoptosis Measurement
Cells were transfected with the HECTD3 siRNA and control
siRNA for 2 days. Different concentrations of cisplatin (Sigma) were
added for 24 hours, if applied. The cell viability was measured by the
sulforhodamine B (SRB) assay as described in our previous report [15].
Cleaved PARP and/or cleaved Caspase-3/7 protein levels were detected
by Western blot.
Statistical Analysis
All experiments were repeated two to three times. Apoptosis experi-
ments were conducted in triplicate. When appropriate, the data were
pooled to generate means ± SD and analyzed by t test.
Results
HECTD3 Promotes Cancer Cell Survival from Cisplatin
To determine HECTD3’s role in cancer development and therapy,
we knocked down endogenous HECTD3 in the MCF7 breast cancer
cell line and HeLa and then treated the cells with cisplatin, a common
DNA-damaging chemotherapeutic drug. In these cancer cells,
HECTD3 depletion dramatically increased the efficacy of cisplatin
as determined by PARP/Caspase-3/7 cleavage and cell viability assays
(Figure 1, A and B). Similar results were observed in the prostate
cancer cell line PC-3 using two different HECTD3 siRNAs
(Figure W1, A and B) and the breast cancer cell line MDA-MB-231
using HECTD3 shRNA (Figure W1, C and D). HECTD3 stable
depletion also sensitized MDA-MB-231 to cisplatin in severe com-
bined immunodeficiency (SCID) mice (Figure W1E ).
HECTD3 depletion itself also slightly decreased cell viability in
HeLa (Figure 1B) and MDA-MB-231 (Figure W1D) and also sen-
sitized HeLa cells to other chemotherapeutic drugs, such as docetaxel
(Figure W2, A and B), and γ radiation (Figure W2C ). However,
HECTD3 depletion did not affect γ radiation–induced foci forma-
tion of γ-H2Ax and BRCA1/Rad51 (Figure W2D). These results
indicated that radiosensitization activity resulting from HECTD3
depletion is not caused by an impaired homologous recombination,
a major mechanism required for repairing DNA damage caused by
ionizing radiation.
We found that depletion of Caspase-8 largely blocked cisplatin-
induced apoptosis in HECTD3-depleted HeLa cells (Figure 1, C
and D). Similar results were observed in MCF7 (Figure W3, A and
B). A Caspase-8 inhibitor also rescued apoptosis of both MCF7 and
HeLa cells induced by cisplatin and HECTD3 depletion (Figure W3,
C and D). We concluded that cisplatin-induced cell apoptosis is exe-
cuted through activation of Caspase-8.
WhenHECTD3was overexpressed in immortalized breast epithelial
cell lines 184B5 and MCF10A, cell growth was not affected (Figure 1,
E and F). However, after the cells were challenged with cisplatin, the
cells with HECTD3 overexpression displayed a significant decrease in
cisplatin-induced apoptosis, as detected by the cleavage of Caspase-3
and PARP and the loss of cell viability (Figure 1, E and F).
HECTD3 Interacts with MALT1 through DOC/DD
HECTD3 possesses an HECT domain at the C terminus and a
DOC domain at the N terminus (Figure 2A), which is the protein
interaction domain that may be responsible for recruiting substrates.
To identify substrates for HECTD3, we used N-terminal HECTD3
(HΔ512-861) as a bait to screen HECTD3-interacting proteins using
the matchmarker yeast two-hybrid (Y2H) system. We identified and
validated MALT1 (#6), PON2, SF3B1, and FBP2 as candidate
HECTD3-interacting proteins under the most stringent condition
(-Ade/-His/-Trp/-Leu/X-α-Gal) (Figure 2B).
The protein-protein interaction between HECTD3 and MALT1
was further confirmed by IP experiments. Flag-HECTD3 andMALT1
were co-transfected into HEK293T cells. When Flag-HECTD3 was
immunoprecipitated by anti-Flag Ab,MALT1was co-immunoprecipitated
(Figure 2C ). In consistency with the Y2H results, the N-terminal
HECTD3 (HΔ512-861) is sufficient for binding to MALT1. When
the DOC domain is deleted from HECTD3 (HΔ109-393), the
protein interaction was largely abolished (Figure 2C ). Additionally,
we performed GST pull-down experiments through generation of a
series of truncated HECTD3 GST-fusion protein and demonstrated
that HECTD3 (109-393) is sufficient for MALT1 interaction
(Figure 2D). Together, these results suggest that HECTD3 interacts
with MALT1 through the DOC domain.
We further performed reciprocal IP experiments by transfect-
ing Flag-MALT1 and HECTD3 into HEK293T cells. When
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Figure 1. HECTD3 promotes cell survival from cisplatin. (A) HECTD3 knockdown by siRNA sensitized MCF7 and HeLa to cisplatin-
induced apoptosis, as detected by the PARP and Caspase-3/7 cleavage. MCF7 is a Caspase-3–deficient cell line [17]. Cisplatin was added
for 1 day after cells were transfected with siRNA for 2 days. (B) HECTD3 knockdown by siRNA significantly sensitized MCF7 and HeLa
to cisplatin-induced apoptosis, as determined by the loss of cell viability. Cell viability was detected by the SRB assay. **P < .01 (t test).
(C) HECTD3 knockdown sensitized HeLa to cisplatin-induced apoptosis in a Caspase-8–dependent manner. Caspase-8 was knocked
down by siRNA. Apoptosis was measured by the cleavage of Caspase-8, Caspase-3, Caspase-7, and PARP. (D) HECTD3 knockdown
sensitized HeLa to cisplatin-induced apoptosis and was rescued by the depletion of Caspase-8. Cell viability was detected by the SRB
assay. (E) HECTD3 overexpression decreased cisplatin-induced apoptosis in 184B5 and MCF10A. HECTD3 was stably overexpressed
in 184B5 and MCF10A by lentivirus. Apoptosis was measured by the cleavage of Caspase-3 and PARP. (F) HECTD3 overexpression
decreased cisplatin-induced apoptosis in 184B5 and MCF10A. Cell viability was detected by the SRB assay. *P < .05, **P < .01 (t test).
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Figure 2. HECTD3 interacts with MALT1 through DOC/DD. (A) Schematic representation of HECTD3 and MALT1 proteins and their trun-
cation mutants. (B) HECTD3 interacts with MALT1 by Y2H. HECTD3Δ512-861 was used as the bait for screening. Eight candidates were
confirmed on the plate. The interaction between p53 and the simian virus 40 large T antigen was used as the positive control. The
HECTD3Δ512-861 and the simian virus 40 large T antigen were used as the negative control. Yeast was cultured on plates with complete
media (YPD) and on plates with QDO (-Ade/-His/-Trp/-Leu) media plus X-α-Gal. All yeast clones grew well in YPD media, but only positive
clones grew well in QDO media and are in blue. (C) HECTD3 interacts with MALT1 through the 109-393 region, which contains the DOC
domain. Flag-HECTD3 and its mutants were co-transfected with MALT1 into HEK293T as indicated for 2 days, and IP was performed using
the anti-FlagM2 beads. MALT1 was probed by the anti-MALT1 Ab. HECTD3Δ110-393 significantly decreased the binding with MALT1 com-
pared to HECTD3. Deletion of the HECT domain in HECTD3 did not affect the protein interaction. LacZ was used as the negative control.
(D) The 109-393 region of HECTD3 is sufficient for MALT1 binding as determined by the GST pull-down assay. Different GST-fused HECTD3
fragments were co-expressed with MALT1 in HEK293T and precipitated by glutathione beads. GST alone was used as the negative control.
(E) MALT1 interacts with HECTD3 through DD. Flag-MALT1 and Flag-MALT1ΔDD (Δ1-126) were co-transfected with HECTD3 into HEK293T,
and IPwas performedwith anti-FlagM2 beads. Deletion of DD fromMALT1 decreased the binding to HECTD3. (F) DD ofMALT1 is sufficient
for HECTD3 binding. GST-fused MALT1 DD and the GST negative control were co-transfected with Flag-HECTD3 into HEK293T for 2 days.
GST pull-down assay was used to detect protein-protein interaction. (G) Binding affinity and kinetic analysis of the interactions between the
HECTD3 DOC domain and the MALT1 DD. The concentrations for the injected HECTD3 DOC samples were from 8 to 0.5 μM, with two-fold
dilutions. Global fitting of data to a 1:1 bindingmodel is shown in black. The purified recombinant proteins for HECTD3DOC andMALT1 DD
are shown on the left side, as analyzed by SDS–polyacrylamide gel electrophoresis.
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Flag-MALT1 was immunoprecipitated by anti-Flag Ab, HECTD3
was co-immunoprecipitated (Figure 2E ). MALT1 contains a death
domain (DD) at its N terminus (Figure 2A), and the MALT1ΔDD
(1-126) mutant did not interact with HECTD3 (Figure 2E ), sug-
gesting that the DD of MALT1 is essential for interaction with
HECTD3. Moreover, DD is also sufficient to bind to HECTD3 as
the GST-DD protein pulled down HECTD3, whereas GST alone did
not (Figure 2F).
Finally, we expressed and purified recombinant HECTD3-DOC
and MALT1-DD from bacteria and tested the direct protein-protein
interaction by SPR detection with a BIAcore 3000 System (GE
HealthCare). A K d of 2.1 × 10
−6 indicated a strong binding between
Figure 3. HECTD3 promotes MALT1 non–K48-linked polyubiquitination and increases the MALT1 protein stability. (A) HECTD3 increased
MALT1 ubiquitination in E3 ligase–independent manner in HEK293T cells. HEK293T cells were co-transfected with expressing plasmids
for HA-Ub, HECTD3-C744, 823A (a catalytic inactive HECTD3 mutant), and Flag-MALT1 as indicated for 2 days. IP was performed with
the anti-Flag M2 beads under a denaturing condition. Western blot was performed with the indicated Abs. (B) HECTD3 promotes MALT1
non–K48-linked polyubiquitination. HA-tagged Ub and mutants (K48 only, K63 only, K48R, and K63R), HECTD3, and Flag-MALT1 were
co-transfected into HEK293T. K48-only Ub hardly supported HECTD3-mediated MALT1 ubiquitination. K63-only Ub partially supported
HECTD3-mediated MALT1 ubiquitination. Both K48R and K63R Ub did not decrease HECTD3-mediated MALT1 ubiquitination. (C)
HECTD3 overexpression decreased the endogenous MALT1 protein degradation in HEK293FT cells, as detected by the CHX chase
assay. MG132 blocked the degradation of MALT1. The cells were incubated with 50 μg/ml CHX for different times (4, 8, and 12 hours)
and were collected for Western blot. β-actin was used as the control. (D) Quantitative data of C. The protein half-life of MALT1 is more
than 12 hours in HEK293T cells. HECTD3 overexpression or MG132 delayed the degradation of MALT1.
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HECTD3-DOC (240-378) and MALT1-DD (Figure 2G ). Taken
together, our experiments suggest that MALT1 directly interacts with
HECTD3 DOC through DD.
HECTD3 Promotes Non–K48-Linked
MALT1 Polyubiquitination
Because the HECTD3 E3 ligase interacts with MALT1, we next
determined whether HECTD3 ubiquitinates MALT1. The expres-
sion constructs for HECTD3, Flag-MALT1, and HA-Ub were co-
transfected into HEK293T cells. Flag-MALT1 was immunoprecipitated
with anti-Flag Ab-conjugated M2 beads under a denatured condition.
The ubiquitinated MALT1 proteins were detected by Western blot
with the anti-HA Ab. As shown in Figure 3A, HECTD3 significantly
increased the ubiquitination of MALT1 compared to the vector con-
trol. Interestingly, the catalytic inactive HECTD3 mutant (C744,
823A) also increased the MALT1 ubiquitination, although less signifi-
cant than that by the wild type (WT) HECTD3. These results sug-
gested that HECTD3 may directly ubiquitinate MALT1 and may
also facilitate MALT1 ubiquitination by other E3 ligases.
To determine the HECTD3-mediated MALT1 poly-Ub chain
linkage, we used several Ub mutants in which K48 and K63 residues
were substituted with arginine (K48R and K63R), respectively, or in
which all K residues were substituted with arginine except K48 and
K63 (K48 only and K63 only). As shown in Figure 3B, HECTD3-
mediated MALT1 poly-Ub chains are not through K48 because
K48-only Ub does not, but K48R Ub supports HECTD3-mediated
MALT1 ubiquitination. In addition, HECTD3-mediated MALT1
poly-Ub chains are partially through K63 because both K63-only
Figure 4. HECTD3 increases the MALT1 protein stability. (A) Overexpression of HECTD3 increased the endogenous MALT1 protein level in
MDA-MB-231. The ratios between MALT1 and β-actin are shown below the panel. (B) Knockdown of HECTD3 in both HeLa and MCF7
decreased the endogenous protein levels of MALT1, especially when the cells were treated with cisplatin. The ratios between MALT1
and β-actin are shown below the panel. (C) Knockdown of HECTD3 decreased the protein half-life of MALT1, as measured by CHX chase
assays. HeLa cells were transfected with anti-HECTD3 and luciferase control siRNAs for 2 days. MG132 partially rescued the HECTD3
depletion–induced MALT1 degradation. (D) Quantitative results of C by the ImageJ software. The β-actin–normalized MALT1 protein levels
at 0 hour were defined as 100% for each panel. (E) Cisplatin decreased the protein half-life of MALT1. HeLa cells were transfected with
HECTD3 and control siRNAs for 2 days. The cells were incubated with 30 μM cisplatin and 50 μg/ml CHX for different times (2–10 hours)
and were harvested for Western blot. (F) Quantitative results of E by the ImageJ software. The β-actin–normalized MALT1 protein levels at
0 hour were defined as 100% for each panel.
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Ub and K63R Ub partially support MALT1 ubiquitination (Fig-
ure 3B). Our results indicated that HECTD3 may also ubiquitinate
MALT1 through a yet identified Ub linkage other than K48 and
K63, because both K48R and K63R support MALT1 ubiquitination
by HECTD3.
HECTD3 Increases the MALT1 Protein Stability
K48-linked polyubiquitination is well known to target substrate
proteins for proteasomal degradation. Because HECTD3-mediated
MALT1 ubiquitination is not through K48, HECTD3 may not
promote MALT1 degradation. Indeed, both endogenous and exoge-
nous MALT1 proteins showed a long protein half-life (>12 hours) in
HEK293T cells, as determined by the cycloheximide (CHX) chase
assays (Figures 3, C and D, and W4A). MG132, a proteasome inhib-
itor, can protect MALT1 from degradation. Surprisingly, HECTD3
increased the MALT1 protein stability in HEK293T cells (Figures 3,
C and D, and W4A) and HECTD3 overexpression also increased the
steady level of MALT1 in MDA-MB-231 cells (Figure 4A).
To investigate whether endogenous HECTD3 regulates the protein
stability of MALT1, we knocked down HECTD3 in both HeLa and
MCF7 and treated the cells with cisplatin. Knockdown of HECTD3
modestly decreased the protein levels of MALT1 in both cell lines,
and the decrease became very dramatic in the presence of cisplatin
(Figure 4B). CHX chase assays were again performed to measure the
MALT1 protein half-lives. Depletion of HECTD3 in HeLa cells in-
creased the MALT1 protein proteasomal degradation that was blocked
by MG132 (Figure 4, C and D). Interestingly, cisplatin treatment
also decreased the MALT1 protein half-life in HeLa (Figure 4, E
and F). Depletion of HECTD3 in combination with cisplatin further
shortened the MALT1 protein half-life in HeLa (Figure 4, E and F).
Taken together, our results indicated that HECTD3-MALT1 interactions
stabilize MALT1 in cells.
Figure 5. Knockdown of MALT1 sensitizes MCF7 and HeLa to cisplatin. (A) Knockdown of MALT1 by siRNA in MCF7 increased cisplatin-
induced apoptosis as detected by Caspase-8/7 and PARP cleavage. HECTD3 siRNA was used as the positive control. (B) Knockdown of
MALT1 by siRNA in HeLa increased cisplatin-induced apoptosis as detected by Caspase-8/3/7 and PARP cleavage. (C) Knockdown of
MALT1 by siRNA in MCF7 significantly increased cisplatin-induced loss of cell viability as measured by SRB assays. MALT1 is a weaker
pro-survival protein compared to HECTD3. (D) Knockdown of MALT1 by siRNA in HeLa significantly increased cisplatin-induced loss of
cell viability as measured by SRB assays.
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MALT1 Promotes Cancer Cell Survival from Cisplatin
The function of MALT1 in cancer chemotherapeutic drug resistance
has not been previously tested. We knocked down MALT1 in MCF7
by two different siRNAs, treated the cells with cisplatin, and examined
apoptosis by Caspase-8 and PARP cleavage and cell viability. As a result,
knockdown of MALT1 sensitized MCF7 to cisplatin (Figure W4B).
As shown in Figure 5, A and B, MALT1 depletion partially mimicked
the results of HECTD3 depletion in both MCF7 and HeLa. Knock-
down of either HECTD3 or MALT1 increased the cleavage of
Caspase-8, Caspase-3/7, and PARP in the presence of cisplatin. The
cell viability assays further confirmed these results. Depletion of MALT1
decreased cell viability in the presence of cisplatin in both MCF7 and
HeLa (Figure 5, C andD). However, MALT1 depletion showed weaker
proapoptotic effects compared to HECTD3 depletion in both cell lines
(Figure 5).
HECTD3 Promotes the Cancer Cell Survival through MALT1
Given that both HECTD3 and MALT1 have pro-survival func-
tion and that HECTD3 protects MALT1 from degradation, it seems
plausible that HECTD3 functions through MALT1. To test this
hypothesis, MALT1 was stably overexpressed in MCF7. Knockdown
of HECTD3 decreased the exogenous MALT1 protein levels (Fig-
ure 6A). Importantly, overexpression of MALT1 obviously reduced
apoptosis (Caspase-8/7 and PARP cleavage) induced by HECTD3
siRNA in combination with cisplatin (Figure 6A). In consistency with
this result, the loss of cell viability induced by HECTD3 siRNA and
cisplatin was largely rescued by MALT1 overexpression in MCF7
(Figure 6B).
Discussion
HECTD3 is a novel HECT-type E3 ligase that, as we have demon-
strated in this study, protects cancer cells from cisplatin-mediated
apoptosis. Several lines of evidence support the notion that HECTD3
functions partially through MALT1: 1) HECTD3 interacts with
MALT1 as determined by Y2H, CO-IP, GST pull-down, and SPR
experiments; 2) HECTD3 promoted MALT1 non-degradative poly-
ubiquitination and increased the protein stability of MALT1, especially
in the presence of cisplatin; 3) the knockdown of either HECTD3 or
MALT1 sensitized cancer cells to cisplatin; and 4) overexpression of
MALT1 partially rescued the apoptosis induced by HECTD3 ablation
in the presence of cisplatin.
HECTD3 has been shown to ubiquitinate Tara [5] and Syntaxin-8
[6]. However, neither Tara nor Syntaxin-8 has been implicated in drug
resistance in cancer and the function of HECTD3 in cancer cells in
response to chemotherapeutic drugs is largely unknown.Here, we demon-
strated that HECTD3 depletion in multiple cancer cell lines, such as
HeLa, MCF7, MDA-MB-231, and PC-3, increased the efficacy of
cisplatin (Figures 1 and W1). Furthermore, HECTD3 depletion sen-
sitized HeLa to docetaxel and γ irradiation (Figure W2). These results
suggest that HECTD3 may be a potential therapeutic target for cancer
combination therapy.
The increased sensitivity to cisplatin by HECTD3 depletion depends
on Caspase-8 because Caspase-8 depletion or inhibition abrogated
the effect of HECTD3 depletion in apoptosis in HeLa and MCF7 (Fig-
ures 1 and W3). In our study, MALT1 was identified as an HECTD3-
interacting protein (Figure 2). MALT1 is well known to play a key role
in NF-κB signaling in response to T cell or B cell receptor signaling
and MALT lymphoma [16]. Recurrent chromosomal translocation
t(11,18)(q21;q21) in MALT lymphoma leads to the production of a
fusion oncoprotein, API2-MALT1, which constitutively and strongly-
actives NF-κB [16]. MALT1 is ubiquitinated by TRAF6 with K63-
linked poly-Ub chains that provide docking surfaces for IKKγ/NEMO
and trigger NF-κB signaling [7]. Additionally, MALT1 interacts with
Caspase-8 and facilitates Caspase-8–mediated c-FLIPL cleavage [11].
There is no data available, however, on the function of MALT1 in solid
tumors. While we found that MALT1 also promotes cancer cell survival
from cisplatin in MCF7 and HeLa (Figures 5 and 6), the functional
mechanism of MALT1 in solid tumors needs further investigations.
We also demonstrated that HECTD3 promotes MALT1 non–K48-
linked polyubiquitination (Figure 3). Interestingly, the catalytic
Figure 6. MALT1 overexpression rescued HECTD3 depletion–induced increase of cisplatin sensitivity in MCF7. (A) Stable MALT1 over-
expression decreased Caspase-8/7 and PARP cleavage induced by ablation of HECTD3 and cisplatin. MALT1 was transduced into MCF7
by the lentiviral system. LacZ was used as a negative control. Blasticidin (10 μg/ml)–resistant cell populations were used for siRNA
transfection for 2 days and cisplatin treatment for overnight. Western blot was performed with the indicated Abs. (B) Stable MALT1
overexpression decreased loss of cell viability induced by ablation of HECTD3 and cisplatin. Cell viability was measured by SRB assays.
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inactive HECTD3 also increased MALT1 ubiquitination, suggesting
that MALT1 may not be a direct substrate of HECTD3. Potentially,
HECTD3 promotes MALT1 ubiquitination by other E3s. TRAF6 is
an E3 ligase that mediates MALT1 poly-Ub with K63-linked chains
[7]. Although we have not directly tested this hypothesis, we observed
that MALT1 poly-Ub chains mediated by HECTD3 appear to con-
tain both K63-linked and non-K63–linked. These results indicate that
HECTD3 may 1) directly ubiquitinate MALT1, 2) facilitate MALT1
ubiquitination by TRAF6, and/or 3) facilitate MALT1 ubiquitination
by other E3s in addition to TRAF6. Our data suggest that MALT1
degradation depends on the proteasome system because the proteasome
inhibitor MG132 blocked the degradation of MALT1. It is very likely
that HECTD3-mediated non–K48-linked polyubiquitination com-
petes with K48-linked polyubiquitination in MALT1 and, therefore,
protects MALT1 from proteasomal degradation.
Nevertheless, HECTD3 increases the MALT1 protein stability by
preventing its proteasomal degradation.MALT1 is actually a very stable
protein with a long half-life; however, cisplatin significantly decreased
MALT1 stability, especially in the absence of HECTD3 (Figure 4),
although the specific mechanism by which cisplatin triggers MALT1
degradation remains unclear.
In summary, we have identified a new function of HECTD3 in
chemotherapeutic drug cisplatin-induced apoptosis. By forming a
complex with MALT1, HECTD3 promotes MALT1 non-degradative
polyubiquitination and increases MALT1 protein stability, which con-
ferred cisplatin resistance. Our results suggest that HECTD3 and
MALT1 are novel pro-survival proteins, and inhibition of HECTD3
or MALT1 may be promising strategies for future cancer therapy.
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Figure W1. HECTD3 depletion increases cisplatin-induced apoptosis and tumor growth. (A) HECTD3 knockdown by two different siRNAs
sensitized the PC-3 prostate cancer cells to cisplatin-induced apoptosis, as detected by PARP and Caspase-3 cleavage. Cisplatin was
added 1 day after the cells were transfected with siRNA for 2 days. (B) HECTD3 knockdown by siRNA significantly sensitized PC-3 to
cisplatin-induced apoptosis, as determined by the loss of cell viability detected by SRB assays. **P < .01 (t test). (C) Stable knockdown
of HECTD3 by shRNA sensitized the MDA-MB-231 breast cancer cells to cisplatin-induced apoptosis, as detected by the Caspase-8,
Caspase-3, and Caspase-7 cleavage. The Hsi#1 siRNA target sequence was chosen for preparing the HECTD3 shRNA construct in the
pSIH1-H1-Puro shRNA vector. (D) Stable knockdown of HECTD3 by shRNA decreased cell growth and sensitized the MDA-MB-231 breast
cancer cells to cisplatin-induced apoptosis, as detected by the loss of cell viability and by SRB assays. *P< .05; **P< .01 (t test). (E) Stable
knockdown of HECTD3 by shRNA sensitized MDA-MB-231 xenografts to cisplatin in SCID mice. In total, twenty-four 4- to 5-week-old SCID
mice were purchased from Harlan (Indianapolis, IN) and randomly distributed into two even groups (Lucsh and HECTD3sh). Tumor cells
(2.0 × 106) were subcutaneously injected into the fat pad of both sides of each mouse. Tumor volumes were measured twice a week and
calculated as 1/2 × length × width2. When the tumor volume reached 300 ± 50 mm3, the mouse was injected with cisplatin (20 mg/kg)
twice a week. All mice were sacrificed after 3 weeks of cisplatin treatment. *P < .05; **P < .01 (t test).
Figure W2. HECTD3 depletion increases docetaxel and γ irradiation–induced apoptosis but does not affect DNA repair in HeLa. (A) HECTD3
knockdown by siRNA sensitized HeLa to docetaxel (10 nM)–induced apoptosis, as detected by PARP and Caspase-3 cleavage. (B) HECTD3
knockdown by siRNA significantly decreased cell growth and sensitized HeLa to docetaxel (10 nM)–induced apoptosis, as determined by
loss of cell viability detected by SRB assays. **P< .01 (t test). (C) HECTD3 knockdown by siRNA significantly sensitized HeLa to γ irradiation–
induced apoptosis, as determined by the colony formation assays. *P< .05; **P< .01 (t test). (D) Percentage of cells with positive BRCA1,
γ-H2Ax, or Rad51 foci following exposure to irradiation (8 Gy, 6 hours) is similar in HeLa cells with or without HECTD3 depletion. The
representative microphotographs of irradiation-induced foci in HeLa cells transfected with the Lucsi control or HECTD3 siRNA are shown.
Cellswere treatedwith 8-Gy irradiation and then fixed6hours laterwith 4%paraformaldehyde, blocked, andstainedwith anti-BRCA1, γ-H2Ax,
or Rad51 antibodies. 4′,6-Diamidino-2-phenylindole (DAPI) was used to stain cell nuclei. The percentage of cellswith positive foci is shownon
the right. The cells with more than 10 foci were considered as positive.
Figure W3. Depletion or inhibition of Caspase-8 at least partially rescues the HECTD3 siRNA proapoptotic function in the presence of
cisplatin. (A) MCF7 cells were transfected with siRNAs for 48 hours and treated with cisplatin. Apoptosis was measured by Caspase-8,
Caspase-7, and PARP cleavage. (B) Caspase-8 depletion in MCF7 partially rescued the HECTD3 siRNA and cisplatin-induced cell viability
decrease as measured by SRB assays. **P < .01 (t test). (C) The Caspase-8 inhibitor at least partially rescued the HECTD3 siRNA and
cisplatin-induced apoptosis. MCF7 and HeLa cells were transfected with siRNAs for 1 day. InSolution Caspase-8 inhibitor II (Calbiochem,
Philadelphia, PA, Cat. No. 218840) was added to the cells for 4 hours. Following that, cisplatin (30 μM) was added for 24 hours. Apoptosis
was measured by Caspase-8, Caspase-3, Caspase-7, and PARP cleavage. (D) The Caspase-8 inhibitor at least partially rescues the HECTD3
siRNA and cisplatin-induced apoptosis in MCF7 and HeLa. Cell viability was measured by SRB assays. **P < .01 (t test).
Figure W4. HECTD3 increases MALT1 protein stability and promotes MCF7 survival from cisplatin. (A) HECTD3 overexpression decreased
the exogenous MALT1 protein degradation in HEK293FT cells, as detected by the CHX chase assay. MG132 blocked the degradation of
MALT1. The cells were incubated with 50 μg/ml CHX for different times (4, 8, and 12 hours) and were collected for Western blot. β-actin
was used as the control. The exposure times for each panel have been adjusted to better compare protein half-lives. Quantitative data
were shown on the right. HECTD3 overexpression or MG132 delayed the degradation of MALT1. (B) MALT1 knockdown by two different
siRNAs sensitized MCF7 cells to cisplatin-induced apoptosis, as detected by the PARP and Caspase-8 cleavage (left) and loss of cell viability
detected by SRB assays (right). *P < .05 (t test).
